Cambridge Trust Company Lowered By $3.04 Million Its Medtronic Plc Shs (MDT) Stake, Acceleron Pharma (XLRN) Had 7 Analysts Last Week

May 19, 2017 - By Adrian Mccoy

Cambridge Trust Company decreased Medtronic Plc Shs (MDT) stake by 11.83% reported in 2016Q4 SEC filing. Cambridge Trust Company sold 42,747 shares as Medtronic Plc Shs (MDT)’s stock 0.00%. The Cambridge Trust Company holds 318,637 shares with $22.70 million value, down from 361,384 last quarter. Medtronic Plc Shs now has $112.80B valuation. The stock declined 0.14% or $0.11 reaching $83.12 per share. About 4.78M shares traded or 19.80% up from the average. Medtronic plc. Ordinary Shares (NYSE:MDT) has risen 6.00% since April 19, 2017 and is uptrending. It has by 0.00% the S&P500.

Among 10 analysts covering Acceleron Pharma (NASDAQ:XLRN), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Acceleron Pharma had 15 analyst reports since August 13, 2015 according to SRatingsIntel. Citigroup upgraded the stock to “Buy” rating in Thursday, March 2 report. Morgan Stanley initiated Acceleron Pharma Inc (NASDAQ:XLRN) rating on Thursday, August 13. Morgan Stanley has “Overweight” rating and $50 target. The firm has “Neutral” rating given on Thursday, September 29 by Citigroup. The rating was initiated by Barclays Capital on Wednesday, April 27 with “Overweight”. The rating was initiated by Janney Capital on Thursday, December 17 with “Neutral”. Barclays Capital maintained the shares of XLRN in report on Monday, June 13 with “Overweight” rating. The stock of Acceleron Pharma Inc (NASDAQ:XLRN) has “Outperform” rating given on Thursday, January 21 by Credit Suisse. The firm earned “Outperform” rating on Friday, January 15 by FBR Capital. Oppenheimer initiated Acceleron Pharma Inc (NASDAQ:XLRN) on Tuesday, December 13 with “Outperform” rating. The stock of Acceleron Pharma Inc (NASDAQ:XLRN) earned “Outperform” rating by Oppenheimer on Friday, November 20. See Acceleron Pharma Inc (NASDAQ:XLRN) latest ratings:

17/05/2017 Broker: Goldman Sachs Rating: Sell New Target: $20.00 Initiates Coverage On
14/03/2017 Broker: JP Morgan Rating: Neutral New Target: $33.00 Initiates Coverage On
02/03/2017 Broker: Nomura Rating: Buy Initiates Coverage On
02/03/2017 Broker: Citigroup Old Rating: Neutral New Rating: Buy Old Target: $40.00 New Target: $36.00 Upgrade
13/12/2016 Broker: Oppenheimer Rating: Outperform Initiate

Analysts await Medtronic plc. Ordinary Shares (NYSE:MDT) to report earnings on May, 25 before the open. They expect $1.31 EPS, up 3.15% or $0.04 from last year’s $1.27 per share. MDT’s profit will be $1.78 billion for 15.86 P/E if the $1.31 EPS becomes a reality. After $1.12 actual EPS reported by Medtronic plc. Ordinary Shares for the previous quarter, Wall Street now forecasts 16.96% EPS growth.

Among 24 analysts covering Medtronic (NYSE:MDT), 15 have Buy rating, 0 Sell and 9 Hold. Therefore 63% are positive. Medtronic had 35 analyst reports since August 10, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Guggenheim on Thursday, June 9. The company was maintained on Friday, April 21 by Northland Capital. RBC Capital Markets maintained the stock with “Outperform” rating in Tuesday, September 29 report. UBS maintained Medtronic plc. Ordinary Shares (NYSE:MDT) rating on Friday, February 17. UBS has “Buy” rating and $94 target. The rating was maintained by SunTrust with “Buy” on Monday, June 13. The firm has “Conviction Buy List” rating by Goldman Sachs given on Friday, November 13. As per Thursday, March 23, the company rating was maintained by Oppenheimer. The rating was maintained by Jefferies on Friday, August 26 with “Buy”. The firm earned “Buy” rating on Wednesday, April 19 by RBC Capital Markets. The firm has “Overweight” rating by Barclays Capital given on Wednesday, November 23.

Cambridge Trust Company increased Home Depot Inc (NYSE:HD) stake by 8,348 shares to 92,170 valued at $12.36 million in 2016Q4. It also upped Eaton Vance Corp (NYSE:EV) stake by 11,731 shares and now owns 163,194 shares. General Electric Co (NYSE:GE) was raised too.

Investors sentiment increased to 0.81 in Q4 2016. Its up 0.08, from 0.73 in 2016Q3. It increased, as 115 investors sold MDT shares while 468 reduced holdings. 123 funds opened positions while 351 raised stakes. 1.09 billion shares or 8.84% more from 999.44 million shares in 2016Q3 were reported. Chevy Chase Trust holds 1.24 million shares or 0.47% of its portfolio. Oakwood Management Limited Liability Corporation Ca, a California-based fund reported 41,632 shares. Old Dominion Management has invested 0.8% in Medtronic plc. Ordinary Shares (NYSE:MDT). Needham Invest Management Limited Liability Corp stated it has 1.06% of its portfolio in Medtronic plc. Ordinary Shares (NYSE:MDT). Winslow Evans And Crocker accumulated 4,474 shares. Norinchukin Retail Bank The has 0.25% invested in Medtronic plc. Ordinary Shares (NYSE:MDT) for 152,993 shares. Letko Brosseau & Assocs Inc holds 419,910 shares or 0.27% of its portfolio. Riverhead Capital Management Ltd Com stated it has 0.03% of its portfolio in Medtronic plc. Ordinary Shares (NYSE:MDT). Oak Associate Limited Oh has invested 0.15% in Medtronic plc. Ordinary Shares (NYSE:MDT). Woodley Farra Manion Portfolio Mngmt Incorporated, a Indiana-based fund reported 34,538 shares. Tennessee-based Martin And Co Tn has invested 1.35% in Medtronic plc. Ordinary Shares (NYSE:MDT). Primecap Mgmt Company Ca owns 12.77 million shares. Tcw Grp Inc owns 473,626 shares or 0.25% of their US portfolio. Amer Century Companies Inc holds 5.82M shares or 0.45% of its portfolio. Cwm Limited Liability reported 77,977 shares.

Since December 7, 2016, it had 0 insider purchases, and 6 sales for $1.35 million activity. 2,500 Acceleron Pharma Inc (NASDAQ:XLRN) shares with value of $68,611 were sold by Ertel Steven D. $54,916 worth of stock was sold by Kumar Ravindra on Wednesday, January 4. $46,667 worth of stock was sold by MCLAUGHLIN KEVIN F on Wednesday, January 4. Quisel John D sold $46,513 worth of stock. MCGUIRE TERRANCE also sold $1.08 million worth of Acceleron Pharma Inc (NASDAQ:XLRN) shares. $54,916 worth of Acceleron Pharma Inc (NASDAQ:XLRN) was sold by Sherman Matthew L.

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $1.01 billion. The Firm is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. It currently has negative earnings. The Company’s research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta , protein superfamily.

Investors sentiment increased to 1.35 in 2016 Q4. Its up 0.35, from 1 in 2016Q3. It increased, as 21 investors sold Acceleron Pharma Inc shares while 34 reduced holdings. 25 funds opened positions while 49 raised stakes. 31.42 million shares or 3.11% more from 30.48 million shares in 2016Q3 were reported. Prudential Financial Incorporated stated it has 73,730 shares or 0% of all its holdings. Blackrock Institutional Trust Na reported 0% in Acceleron Pharma Inc (NASDAQ:XLRN). Pacad Investment Ltd invested in 3,600 shares or 0.01% of the stock. 482,977 were reported by Franklin Res Inc. Mutual Of America Cap Mngmt Ltd Liability holds 44,691 shares or 0.02% of its portfolio. Blackrock Gp Limited invested in 0% or 276,525 shares. Rhumbline Advisers owns 30,988 shares for 0% of their portfolio. State Of New Jersey Common Pension Fund D stated it has 18,000 shares. Loomis Sayles And Ltd Partnership accumulated 370,424 shares. Blackrock Management Ltd Com, a New Jersey-based fund reported 148,729 shares. Morgan Stanley stated it has 0% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). Royal Fincl Bank Of Canada reported 0% in Acceleron Pharma Inc (NASDAQ:XLRN). Deutsche Bank & Trust Ag holds 281,887 shares. Dupont Cap Management accumulated 12,037 shares or 0.01% of the stock. New York-based Jennison Associate Ltd Liability Com has invested 0% in Acceleron Pharma Inc (NASDAQ:XLRN).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>